Authors and Disclosures
Michael Eller and Peter J Goadsby*
Headache Group – Department of Neurology, University of California, San Francisco, CA, USA
Financial & competing interests disclosure
PJ Goadsby is on the boards of Allergan, Colucid, MAP Pharmaceuticals, Merck Sharpe & Dohme Ltd, eNeura, Neuroaxon, Autonomic Technologies Inc, Boston Scientific, Eli Lilly, Medtronic, Linde Gases, Arteaus, AlderBio and Bristol-Myers Squibb. He has consulted for Gammacore, Pfizer, Nevrocorp, Lundbeck, Zogenix, Impax and Dr.Reddy's, and has been compensated for expert legal testimony. He receives grant support from GlaxoSmithKline, MAP, MSD, eNeura, and Amgen. He has received honoraria for speaking from MSD, Pfizer, Allergan, and Mennarini, and payment for editorial work from Journal Watch Neurology and for developing educational materials for the American Headache Society. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.
*Author for correspondence
pgoadsby@headache.ucsf.edu